1-2 of 2
Hervé Maisonneuve
Close
Sort by
Journal Articles

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Clinical Trials & Observations
Vincent Camus, Cédric Rossi, Pierre Sesques, Justine Lequesne, David Tonnelet, Corinne Haioun, Eric Durot, Alexandre Willaume, Martin Gauthier, Marie-Pierre Moles-Moreau, Chloé Antier, Julien Lazarovici, Hélène Monjanel, Sophie Bernard, Magalie Tardy, Caroline Besson, Laure Lebras, Sylvain Choquet, Katell Le Du, Christophe Bonnet, Sarah Bailly, Ghandi Damaj, Kamel Laribi, Hervé Maisonneuve, Roch Houot, Adrien Chauchet, Fabrice Jardin, Alexandra Traverse-Glehen, Pierre Decazes, Stéphanie Becker, Alina Berriolo-Riedinger, Hervé Tilly
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3862–3872.
https://doi.org/10.1182/bloodadvances.2021004778
Published: 2021
Includes: Supplemental data
Journal Articles

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Clinical Trials & Observations
Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, Rene-Olivier Casasnovas, François Lemonnier, Gian Matteo Pica, Roch Houot, Loic Ysebaert, Hervé Tilly, Jean-Claude Eisenmann, Steven Le Gouill, Vincent Ribrag, Pascal Godmer, Sylvie Glaisner, Guillaume Cartron, Luc Xerri, Gilles André Salles, Thierry Fest, Franck Morschhauser
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3217–3223.
https://doi.org/10.1182/bloodadvances.2020001955
Published: 2020
Includes: Supplemental data